European Union - English - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - acute coronary syndrome - antithrombotic agents - angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (pci), including patients with st-segment-elevation myocardial infarction (stemi) undergoing primary pci.angiox is also indicated for the treatment of adult patients with unstable angina / non-st-segment-elevation myocardial infarction (ua / nstemi) planned for urgent or early intervention.angiox should be administered with aspirin and clopidogrel.

United States - English - NLM (National Library of Medicine)

the medicines company - fentanyl hydrochloride (unii: 59h156xy46) (fentanyl - unii:uf599785jz) - fentanyl 40 ug - ionsys is indicated for the short-term management of acute postoperative pain severe enough to require an opioid analgesic in the hospital and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.3)] , reserve ionsys for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. ionsys is: - only for use in patients who are alert enough and have adequate cognitive ability to understand the directions for use. - not for home use. ionsys is for use only in patients in the hospital. discontinue treatment with ionsys before patients leave the hospital. - for use after patients have been titrated to an acceptable level of analgesia using alternate opioid analgesics. ionsys is contraindicated

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the medicines company uk ltd - bivalirudin - powder for solution for infusion - 250mg

Australia - English - Department of Health (Therapeutic Goods Administration)

the medicines company australia pty ltd - bivalirudin -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the medicines company uk ltd - fentanyl - transdermal system - 40microgram/1dose

United States - English - NLM (National Library of Medicine)

the medicines company - thrombin alfa (unii: sck81amr7r) (thrombin alfa - unii:sck81amr7r) - thrombin alfa 1000 [iu] in 1 ml - recothrom ®, thrombin topical (recombinant), is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age. recothrom may be used in conjunction with an absorbable gelatin sponge, usp. - do not inject directly into the circulatory system. - do not use for the treatment of massive or brisk arterial bleeding. - do not administer to patients with a history of hypersensitivity to recothrom or any components of recothrom. - do not use in patients with known hypersensitivity to hamster proteins. pregnancy category c animal reproduction studies have not been conducted with recothrom. it is also not known whether recothrom can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. recothrom should be give

United States - English - NLM (National Library of Medicine)

the medicines company - cangrelor (unii: 6aq1y404u7) (cangrelor - unii:6aq1y404u7) - cangrelor 50 mg - kengreal is indicated as an adjunct to percutaneous coronary intervention (pci) to reduce the risk of periprocedural myocardial infarction (mi), repeat coronary revascularization, and stent thrombosis (st) in patients who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iib/iiia inhibitor [see clinical studies ( 14.1 )]. kengreal is contraindicated in patients with significant active bleeding [see warnings and precautions ( 5.1 ) and adverse reactions ( 6.1 )] . kengreal is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to kengreal or any component of the product [see adverse reactions ( 6.1 )] . pregnancy category c there are no adequate and well-controlled studies of kengreal in pregnant women. cangrelor did not produce malformations in either the rat or rabbit reproductive studies, and is not considered to be a teratogen. in embryo-fetal development studies in rats, cangrelor produced dose-related fetal growth retardation characteri

Australia - English - Department of Health (Therapeutic Goods Administration)

the medicines company australia pty ltd - clevidipine butyrate; clevidipine -

United States - English - NLM (National Library of Medicine)

ironcompany.com, llc - benzalkonium chloride 0.13%, antiseptic - • for hand sanitizing to decrease bacteria on the skin. • apply topically to the skin to help prevent cross contamination. • recommended for repeated use. • dries in seconds.

United States - English - NLM (National Library of Medicine)

the medicines company - vaborbactam (unii: 1c75676f8v) (vaborbactam - unii:1c75676f8v), meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - vaborbactam 1 g in 2 g - vabomere™ is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli , klebsiella pneumoniae , and enterobacter cloacae species complex. to reduce the development of drug-resistant bacteria and maintain the effectiveness of vabomere and other antibacterial drugs, vabomere should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. vabomere is contraindicated in patients with known hypersensitivity to any components of vabomere (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphyla